Jean-François Boussard, 58, joins Biocitech after a long and successful biotechnology career in both academic and industry fields. From 1994, after six years as Patents, Licensing and Legal Director in a financial holding company, he was an independent consultant in enterprise creation and technology transfer. In 1998, he founded and was CEO of Substrat, a consulting company specialized in enterprise creation and management, project management and technology transfer in the field of biotechnology. His experience at Substrat, which plans to name its new CEO in the next few weeks, makes him exceptionally well qualified to take over the CEO position at Biocitech. Prior to Substrat, Jean-François Boussard was a manager for pharmaceuticals and biotechnology at France's innovation agency, Anvar, from 1982 to 1988. From 1979-82, he was a biologist at LERS Synthelabo after an earlier spell as a research scientist at the University of Metz. He completed a thesis in ecotoxicology at the University of Metz.
"I am delighted to join such a go-ahead organization as Biocitech, one of the key players in biotechnology in France and Europe," said Jean-François Boussard. "I am looking forward to putting my scientific, legal and financial know-how to use to continue the rapid development of the park. My past experience means I know exactly how biotech companies work - and this should enable me to make a real contribution to the efforts made by the team at Biocitech to respond to the needs of our present and future resident companies."
About Biocitech The Biocitech technology park for life sciences offers a world-class environment and services for the development of biotechnology, biopharmaceutical and fine chemical companies. Biocitech is on the outskirts of Paris, only 20 minutes from the city center and Charles de Gaulle airport. It is privately-owned and provides secure premises and comprehensive facilities based on the latest technology. It has received regulatory approval for conformity to environmental protection standards. Companies can use one or many of the services offered. These include offices, laboratories and a range of technical and scientific services - all designed to let entrepreneurs concentrate their time and resources on their core business. Companies already established at Biocitech represent a wide variety of complementary disciplines and many are working on collaborative projects.
Along with other organizations in the Ile-de-France region around Paris, Biocitech plays a key role in the Medicen Paris Region network. This is a healthcare and new therapy cluster designated by the French government as internationally competitive and hence qualified for special privileges. For further information: www.biocitech.com
Best regards,
Lynne Chapman ANDREW LLOYD & ASSOCIATES http://www.ala.com lynne@ala.com
